CMS Colorectal Cancer Drug Policy Will Not Limit Current Off-Label Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services releases its final national coverage determination for Avastin, Erbitux, Eloxatin and Camptosar. The final determination is in line with the draft NCD, covering off-label indications that are included in certain major compendia and are part of nine National Cancer Institute clinical trials.
You may also be interested in...
CMS’ Use Of Data From “Coverage With Evidence Development” Process To Vary
The way data are used will depend on whether information is gathered through a clinical trial, registry or other method, CMS’ Phurrough says. Most data collection methods will not support a change in a national coverage determination, although such information will assist in clinical practice.
CMS’ Use Of Data From “Coverage With Evidence Development” Process To Vary
The way data are used will depend on whether information is gathered through a clinical trial, registry or other method, CMS’ Phurrough says. Most data collection methods will not support a change in a national coverage determination, although such information will assist in clinical practice.
CMS Developing Guidance On Coverage Decisions For Clinical Trials
The guidance will address questions about CMS’ priority setting and methodologies for making coverage decisions in the future. The document will be one of the first produced under CMS’ new guidance development process, details of which will be released in the next two weeks.